Antipsychotic drugs are central to the treatment of schizophrenia and other psychotic
disorders but are ineffective for some patients and associated with side-effects and …

Major depressive disorder (MDD) is one of the most disabling psychiatric disorders.
Approximately one‐third of the patients with MDD are treatment resistant to the current …

The kynurenine pathway (KP) of tryptophan (TRP) catabolism links immune system
activation with neurotransmitter signaling. The KP metabolite kynurenic acid (KYNA) is …

The ability of ketamine administration to activate prefrontal glutamate neurotransmission is
thought to be a key mechanism contributing to its transient psychotomimetic effects and its …

A number of studies have indicated that antagonists of the N‐methyl‐d‐aspartate subtypes
of glutamate receptors can cause schizophrenia‐like symptoms in healthy individuals and …

The N-methyl-d-aspartate receptor (NMDAR) hypofunction hypothesis has been proposed to
help understand the etiology and pathophysiology of schizophrenia. This hypothesis was …

There is converging evidence that high doses of hallucinogenic drugs can produce
significant alterations of self-experience, described as the dissolution of the sense of self …

The observation that antagonists of the N-methyl-D-aspartate receptor (NMDAR), such as
phencyclidine (PCP) and ketamine, transiently induce symptoms of acute schizophrenia had …

Dopamine (DA) and glutamate neurotransmission are strongly implicated in schizophrenia
pathophysiology. While most studies focus on contributions of neurons that release only DA …

Cognitive impairment has been observed in patients with various psychiatric disorders,
including schizophrenia, major depressive disorder (MDD), and bipolar disorder (BD) …